Literature DB >> 18032706

Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways.

Antonio Ruiz-Vela1, Mohit Aggarwal, Paloma de la Cueva, Cezary Treda, Beatriz Herreros, Daniel Martín-Pérez, Orlando Dominguez, Miguel A Piris.   

Abstract

Aberrant inhibition of B-cell receptor (BCR)-induced programmed cell death pathways is frequently associated with the development of human auto-reactive B-cell lymphomas. Here, we integrated loss-of-function, genomic, and bioinformatics approaches for the identification of oncogenic mechanisms linked to the inhibition of BCR-induced clonal deletion pathways in human B-cell lymphomas. Lentiviral (HIV)-based RNA interference screen identified MCL1 as a key survival molecule linked to BCR signaling. Loss of MCL1 by RNA interference rendered human B-cell lymphomas sensitive to BCR-induced programmed cell death. Conversely, MCL1 overexpression blocked programmed cell death on BCR stimulation. To get insight into the mechanisms of MCL1-induced survival and transformation, we screened 41 000 human genes in a genome-wide gene expression profile analysis of MCL1-overexpressing B-cell lymphomas. Bioinformatic gene network reconstruction illustrated reprogramming of relevant oncoproteins within beta-catenin-T-cell factor signaling pathways induced by enforced MCL1 expression. Overall, our findings not only illustrate MCL1 as an aberrantly expressed reprogramming oncoprotein in follicular lymphomas but also highlight MCL1 as key therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032706     DOI: 10.1182/blood-2007-09-110601

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression.

Authors:  Jonathan M Irish; June H Myklebust; Ash A Alizadeh; Roch Houot; Jeff P Sharman; Debra K Czerwinski; Garry P Nolan; Ronald Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-11       Impact factor: 11.205

2.  Overexpression of the c-myc oncogene inhibits nonsense-mediated RNA decay in B lymphocytes.

Authors:  Ding Wang; Jordan Wengrod; Lawrence B Gardner
Journal:  J Biol Chem       Date:  2011-10-03       Impact factor: 5.157

3.  Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.

Authors:  Daniel Martín-Pérez; Esther Sánchez; Lorena Maestre; Javier Suela; Pierfrancesco Vargiu; Lorena Di Lisio; Nerea Martínez; Javier Alves; Miguel A Piris; Margarita Sánchez-Beato
Journal:  Am J Pathol       Date:  2010-06-17       Impact factor: 4.307

4.  Identification of FCER1G related to Activated Memory CD4+ T Cells Infiltration by Gene Co-expression Network and Construction of a Risk Prediction Module in Diffuse Large B-Cell Lymphoma.

Authors:  Xiaoyu Xiang; Li-Min Gao; Yuehua Zhang; Yuan Tang; Sha Zhao; Weiping Liu; Yunxia Ye; Wenyan Zhang
Journal:  Front Genet       Date:  2022-05-30       Impact factor: 4.772

5.  MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma.

Authors:  Giorgio Malpeli; Stefano Barbi; Corinna Greco; Simonetta Zupo; Anna Bertolaso; Maria Teresa Scupoli; Mauro Krampera; Paul Takam Kamga; Carlo Maria Croce; Aldo Scarpa; Alberto Zamò
Journal:  Oncotarget       Date:  2018-04-13

6.  Systems pharmacology and genome medicine: a future perspective.

Authors:  Aislyn D Wist; Seth I Berger; Ravi Iyengar
Journal:  Genome Med       Date:  2009-01-22       Impact factor: 11.117

7.  Novel prognostic genes of diffuse large B-cell lymphoma revealed by survival analysis of gene expression data.

Authors:  Chenglong Li; Biao Zhu; Jiao Chen; Xiaobing Huang
Journal:  Onco Targets Ther       Date:  2015-11-18       Impact factor: 4.147

8.  Identification of MMP9 as a novel key gene in mantle cell lymphoma based on bioinformatic analysis and design of cyclic peptides as MMP9 inhibitors based on molecular docking.

Authors:  Wei Yan; Shawn Xiang Li; Minjie Wei; Hua Gao
Journal:  Oncol Rep       Date:  2018-09-05       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.